PDAC - Pancreatic Ductal Adenocarcinoma Clinical Trial
Official title:
A Phase 2, Multicenter, Single Arm, Open Label Non-Randomized Study of [68Ga]FAPI-46 PET in Patients With Resectable or Borderline Resectable Pancreatic Ductal Carcinoma
This is a prospective, multi-center, single arm, open label, non-randomized study to evaluate the ability of [68Ga]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC. The [68Ga]FAPI-46 PET scans will be acquired after initial staging using institutional standard methods. If the participant is prescribed neoadjuvant therapy, a second [68Ga]FAPI-46 PET scan will be performed within 21 days prior to planned surgical resection. This will be followed by histopathology and IHC analyses and comparison to resected PDAC tumor specimens.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT06122896 -
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
|
Early Phase 1 | |
Recruiting |
NCT04700488 -
Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)
|
N/A | |
Not yet recruiting |
NCT05947825 -
Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients
|
Phase 2 | |
Recruiting |
NCT06151223 -
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
|
||
Recruiting |
NCT05845801 -
Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer
|
||
Recruiting |
NCT05853198 -
Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability
|
N/A | |
Recruiting |
NCT05669287 -
Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomics
|
N/A | |
Recruiting |
NCT05727020 -
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
|
||
Recruiting |
NCT05218889 -
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05132244 -
Monitoring and Managing Glucose Levels in People With Pancreatic Cancer
|
N/A | |
Recruiting |
NCT04365049 -
Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma
|